In 2013, for the first time, CD19-directed CART (CART 19) cells were successfully used in two children with chemotherapy-resistant ALL, and despite the presence of severe CRS and B-aplasia, CR was achieved in both patients [137]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.